Fiamma Buttitta

University of Chieti-Pescara — Italy

Medicine · Health Sciences

50h-index9.4kcitations160works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(48), Cancer-related Molecular Pathways(34), Cancer Genomics and Diagnostics(29), Ovarian cancer diagnosis and treatment(19), RNA modifications and cancer(14)

Publications160 total

A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade
Pathologica·2024· 3 citedOpen Access
Case Report: The molecular fingerprint and the clinical implication of an exceptional response to neoadjuvant therapy in a metastatic cardia adenocarcinoma
Frontiers in Surgery·2024Open Access
Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor
Human Pathology·2023· 11 cited
POLE exonuclease domain mutations in endometrial carcinoma: a case report
Pathologica·2023· 2 citedOpen Access
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
Pathologica·2023Open Access
Supplementary Table S1 from Effective Assessment of <i>egfr</i> Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
2023Open Access
Supplementary Table S2 from Effective Assessment of <i>egfr</i> Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
2023Open Access
Data from Effective Assessment of <i>egfr</i> Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
2023Open Access
Supplementary Table S1 from Effective Assessment of <i>egfr</i> Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
2023Open Access
Supplementary Table S2 from Effective Assessment of <i>egfr</i> Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
2023Open Access
Data from Effective Assessment of <i>egfr</i> Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
2023Open Access
Supplementary Figure 2 from Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization
2023Open Access
Supplementary Figure 2 from Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization
2023Open Access
Supplementary Figure 1 from Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization
2023Open Access
Supplementary Figure 1 from Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization
2023Open Access
Data from Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization
2023Open Access
Data from Identification of an Aberrantly Spliced Form of HDMX in Human Tumors: A New Mechanism for HDM2 Stabilization
2023Open Access
Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units
Pathologica·2023· 3 citedOpen Access
List of contributors
Elsevier eBooks·2023
Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology
Elsevier eBooks·2023· 1 cited
page 1 of 8Next →

Frequent Co-authors

Antonio Marchetti(29), Lara Felicioni(22), Antonio Marchetti(14), Antonio Chella(13), Sara Malatesta(11), Silvia Pellegrini(10), Maela Del Grammastro(9), Mattia Barbareschi(9), Generoso Bevilacqua(9), Fabio Barassi(7), Felice Mucilli(7), Andrea Mezzetti(7), Paolo Palma(7), Franco Cuccurullo(6), Carlo Alberto Angeletti(6), Giampaolo Filice(5), Claudio Doglioni(5), Rocco Sacco(4), Milo Frattini(4), Aldo Scarpa(4)